Lembaz Survival Approval Rests on External Control Without Matched Precedent
Regulatory Approvals

Lembaz Survival Approval Rests on External Control Without Matched Precedent

Published : 18 Nov 2026

At a Glance
IndicationInfantile-Onset Niemann-Pick Disease Type C
Drugadrabetadex
CompanyMandos, LLC
CategoryRegulatory Milestone
Sub CategoryApproval Granted
Therapeutic AreaRare Diseases & Genetics
Regulatory AgencyU.S. Food and Drug Administration
Approval DateNovember 17, 2026
Risk Reduction55% reduction in the risk of death
Median Survival Time (Treated)8.5 years
Median Survival Time (Control)4.9 years
Patient Weight RequirementAt least 7 kg (about 15 pounds)
Administration RouteIntrathecal injection
Dosing FrequencyEvery two weeks
Regulatory DesignationBreakthrough Therapy designation
Boxed WarningHearing impairment, including permanent hearing loss

FDA Approves Lembaz for Infantile-Onset Niemann-Pick Disease Type C

The U.S. Food and Drug Administration (FDA) has approved Lembaz (adrabetadex) injection, the first treatment demonstrated to extend the lives of patients with infantile-onset Niemann-Pick disease type C (NPC). Approved for adult and pediatric patients weighing at least 7 kg with neurological symptoms appearing before age 6, Lembaz significantly reduced the risk of death by 55% compared to an external control group. Patients treated with Lembaz achieved a median survival time of 8.5 years, versus 4.9 years in the control group. This approval marks a crucial advancement for families facing this rare, inherited lysosomal storage disorder, offering a meaningful treatment option where previous therapies had not shown a survival benefit.

  • Lembaz demonstrated a significant survival benefit for patients with infantile-onset NPC, showing a 55% reduction in the risk of death. The median survival time for treated patients was 8.5 years, compared to 4.9 years in the matched external control group, indicating a substantial improvement in life expectancy for this severe form of the disease.
  • The approval targets a specific and vulnerable patient population: adult and pediatric patients weighing at least 7 kg whose neurological symptoms began before age 6. Lembaz is administered via intrathecal injection every two weeks, a specialized route designed to deliver the therapy directly to the central nervous system, where the progressive neurological decline of NPC primarily occurs.
  • Lembaz received Breakthrough Therapy designation, highlighting its potential to offer a major advance for a serious condition with unmet medical needs. However, the drug carries a boxed warning for hearing impairment, including permanent hearing loss, necessitating comprehensive hearing evaluations before and regularly throughout treatment to monitor and manage this critical safety concern.

Addressing the Critical Unmet Need in Infantile-Onset NPC

Disease-modifying treatment needs to be introduced early in the course of the disease to combat progressive neurodegeneration. The only approved, disease-modifying treatment is a substrate-reduction treatment, miglustat, with limited efficacy. Long-term treatment with intrathecal 2-hydroxypropyl-β-cyclodextrin may suppress neurological deterioration, however disease progression is not completely inhibited.

  • Limited efficacy of miglustat: Given miglustat's limited efficacy, new compounds are under development. All patients showed rapid disease progression despite treatment with miglustat before intrathecal HPBCD treatment.

  • Incomplete and status-dependent benefit of intrathecal cyclodextrin: Patients still experience some disease progression, and the treatment outcome is dependent on the neurological status at the time of diagnosis. Long-term treatment may suppress neurological deterioration, however further optimization of the treatment protocol and additional treatments are needed to improve patient outcomes.

  • Ototoxicity with intrathecal HPβCD: Mid-frequency to high-frequency hearing loss, an expected adverse event, was documented in all participants in the non-randomised, open-label, phase 1-2 trial. Mild-to-moderate hearing loss was observed in three patients treated for 4-11 years, and when managed with hearing aids, this did not have an appreciable effect on daily communication.

  • Drug development hindered by heterogeneity and early-detection gap: The phenotypic heterogeneity and variable course of the disease can impede the development and approval of new agents, and many candidates including gene therapy are still far from clinical use. Awareness of the disease and newborn screening is needed for earlier disease detection, and a combination of treatment strategies should be sought, with a holistic approach, to improve the quality of life of affected individuals and their families.

Understanding the Safety and Tolerability of Lembaz (Adrabetadex)

Published intrathecal adrabetadex (2-hydroxypropyl-β-cyclodextrin, VTS-270) data in Niemann-Pick disease, type C1 describe an acceptable systemic profile with hearing loss as the consistent drug-related effect. Procedural tolerability of repeated lumbar puncture delivery has been characterized over long-term biweekly dosing.

  • In the open-label, dose-escalation phase 1-2a study of monthly intrathecal HPβCD at the National Institutes of Health and every-2-week dosing at Rush University Medical Center, no drug-related serious adverse events were observed. Mid-frequency to high-frequency hearing loss, an expected adverse event, was documented in all participants, and when managed with hearing aids, this did not have an appreciable effect on daily communication.

  • During the first year in 14 monthly-treated participants, two patients had treatment interrupted for one dose, based on grade 1 ototoxicity. Between 12 and 18 months, one participant had treatment interrupted at 17 months due to hepatocellular carcinoma, one patient had dose interruption for 2 doses based on caregiver hardship and one patient had treatment interrupted for 1 dose for mastoiditis.

  • In 59 patients with NPC1 treated with 2935 infusions by lumbar puncture with VTS-270, adrabetadex on a biweekly schedule, 33 (55.9%) had no adverse events ever after an LP and 26 (44.1%) had adverse effects at some time. Of the 2935 LPs, adverse events occurred after 3.3% of LPs, most observed were headache (1.2% of LPs), nausea (0.3%), vomiting (1.0%), and back pain (1.3%).

  • Ototoxicity reflects rapid-onset preferential loss of cochlear outer hair cells (OHCs) within hours of dosing, with dose-dependent severity. Inner hair cells and spiral ganglion cells are spared at doses that cause ~85% OHC loss, and no other major organ systems appear adversely affected, while all patients in the first-to-human phase 1 clinical trial experienced some permanent hearing loss, although a temporary loss of function can be observed acutely following drug delivery.

Frequently Asked Questions

What are the key clinical features and diagnostic considerations for infantile-onset Niemann-Pick Disease Type C?
Infantile-onset Niemann-Pick Disease Type C is a severe neurodegenerative lysosomal storage disorder characterized by progressive neurological decline, hepatosplenomegaly, and pulmonary involvement. Diagnosis often involves a combination of clinical suspicion, biochemical testing for oxysterols, and genetic sequencing to identify mutations in the *NPC1* or *NPC2* genes. Early recognition is crucial due to the rapid progression of symptoms in this population.
How does adrabetadex function as a therapeutic agent for Niemann-Pick Disease Type C?
Adrabetadex is an orally administered small molecule designed to reduce the accumulation of glycosphingolipids, which are implicated in the pathophysiology of Niemann-Pick Disease Type C. It acts as a substrate reduction therapy by inhibiting glucosylceramide synthase, thereby decreasing the synthesis of glucosylceramide. This mechanism aims to mitigate the downstream effects of cholesterol and lipid trafficking defects characteristic of the disease.
What are the current unmet medical needs in treating infantile-onset Niemann-Pick Disease Type C?
Significant unmet needs persist in the treatment of infantile-onset Niemann-Pick Disease Type C, primarily due to its progressive and debilitating neurodegenerative course. Existing therapies often focus on symptomatic management, with limited options that directly address the underlying pathophysiology or significantly alter disease progression. There is a critical demand for disease-modifying treatments that can slow or halt neurological decline and improve long-term outcomes.
What is the potential impact of adrabetadex's development on the management landscape for Niemann-Pick Disease Type C?
The development of adrabetadex represents a significant advancement in the therapeutic landscape for Niemann-Pick Disease Type C, offering a targeted approach to address the core biochemical defect. Its potential to reduce substrate accumulation could lead to improved neurological and systemic outcomes, particularly in the severe infantile-onset form. This therapy aims to provide a much-needed disease-modifying option where only supportive care has largely been available.

References

  1. [1] Zeitlinger M, Rusca A et al.. Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration. International journal of clinical pharmacology and therapeutics. 2012 Jun. 22677302
  2. [2] Kirkegaard T, Roth AG et al.. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature. 2010 Jan 28. 20111001
  3. [3] Lichtenhan JT, Hirose K et al.. Direct administration of 2-Hydroxypropyl-Beta-Cyclodextrin into guinea pig cochleae: Effects on physiological and histological measurements. PloS one. 2017. 28384320
  4. [4] Hoy SM. Diclofenac Sodium Bolus Injection (Dyloject(TM)): A Review in Acute Pain Management. Drugs. 2016 Aug. 27447189
  5. [5] Ravanfar P, Syeda WT et al.. Investigation of Brain Iron in Niemann-Pick Type C: A 7T Quantitative Susceptibility Mapping Study. AJNR. American journal of neuroradiology. 2023 Jul. 37348967
  6. [6] Matsuo M, Sakakibara T et al.. Long-term efficacy of intrathecal cyclodextrin in patients with Niemann-Pick disease type C. Brain & development. 2024 May. 38448301
  7. [7] Zheng YM, Cain YL et al.. [Evaluation of detection of Epstein-Barr virus Rta/IgG in nasopharyngeal carcinoma]. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2009 Aug. 20108775
  8. [8] Thebault C, Ollivier R et al.. Mitochondriopathy: a rare aetiology of restrictive cardiomyopathy. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2008 Nov. 18579503
  9. [9] Cawley NX, Zhou R et al.. Serum neurofilament light protein as a biomarker in Niemann-Pick disease, type C1. Genetics in medicine open. 2025. 40821948
  10. [10] Crumling MA, King KA et al.. Cyclodextrins and Iatrogenic Hearing Loss: New Drugs with Significant Risk. Frontiers in cellular neuroscience. 2017. 29163061
  11. [11] Albert OK, Friedmann K et al.. Low Risk Profile of Long-Term Repeated Lumbar Puncture for Intrathecal Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin in Patients With Niemann-Pick Type C. Pediatric neurology. 2023 Jul. 37201244
  12. [12] Sidhu R, Kell P et al.. Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease. Molecular genetics and metabolism. 2020 Apr. 32033912
  13. [13] Hastings C, Liu B et al.. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial. Molecular genetics and metabolism. 2022 Dec. 36279795
  14. [14] Farmer CA, Thurm A et al.. Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1. CNS drugs. 2019 Jul. 31187454
  15. [15] Wang J, Keshava S et al.. Alterations to Sphingomyelin Metabolism Affect Hemostasis and Thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 2023 Jan. 36412194
  16. [16] Lee MY, Kabara LL et al.. ROS Scavenger, Ebselen, Has No Preventive Effect in New Hearing Loss Model Using a Cholesterol-Chelating Agent. Journal of audiology & otology. 2019 Apr. 30727719
  17. [17] Ding D, Jiang H et al.. Cochlear spiral ganglion neuron degeneration following cyclodextrin-induced hearing loss. Hearing research. 2021 Feb. 33302057
  18. [18] Blair HA, Plosker GL. Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain. Clinical drug investigation. 2015 Jun. 25989733
  19. [19] Porter FD, Alexander DM et al.. Utility of 24(S)-hydroxycholesterol as a proximal biomarker to monitor long-term intrathecal adrabetadex therapy in individuals with Niemann-Pick disease, type C1. Molecular genetics and metabolism. 2025 Dec. 41260183
  20. [20] Bremova-Ertl T, Schneider S. Current advancements in therapy for Niemann-Pick disease: progress and pitfalls. Expert opinion on pharmacotherapy. 2023 May-Aug. 37211769

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts